KDMC part of a new collaboration to improve the accuracy of sepsis tests in the state – Daily Leader


King’s Daughters Medical Center in Brookhaven is one of two Mississippi hospitals selected to participate in a pilot program to improve the accuracy of sepsis tests.

MHA Solutions and Healthcare Providers Insurance (HPIC) are partnering with Magnolia Medical Technologies to further enhance patient safety and improve results across the state of Mississippi.

This new relationship provides all members of the Mississippi Hospital Association (MHA) with educational resources and programs on blood culture best practices and the role of solutions, including Steripath, in virtually eliminating blood culture contamination at the source.

Two MHA member hospitals – KDMC and Neshoba General Hospital in Philadelphia – have been selected to participate in a pilot program sponsored by HPIC to demonstrate the effects of Steripath in reducing blood culture contamination. The aim of the pilot is to establish a standardized model of blood culture collection and contamination prevention that can be followed by other MHA members to improve testing accuracy for circulatory infections such as sepsis and identify unnecessary, preventable health risks and harms to the Mississippi residents avoiding this may result from a misdiagnosis.

“KDMC is pleased to have been selected as one of two hospitals selected by MHA Solutions and HPIC to test the Steripath Specimen Diversion application, which is expected to dramatically improve blood culture collection and become more accurate “Said Cheri Hess Brooks, KDMC’s chief nursing officer. “A common problem is having skin cells drawn with a blood sample, which can lead to a ‘false positive’ result, suggesting an infection that isn’t actually there.

“The Steripath collection process eliminates most errors, saving patients from overdosing on antibiotics and extra days of hospitalization. Both our laboratory and nursing staff are just beginning to learn the new process and we are excited, especially on behalf of our patients, to do something new and highly effective to manage patient care effectively, safely, and with fewer hospital stays. We look forward to the pilot program and started employee training this month. “

Magnolia Medical Technologies is a Seattle-based medical technology company that develops and markets innovative blood culture collection devices that improve the accuracy and predictability of diagnostic test results for sepsis. Its Steripath Initial Specimen Diversion Device is the only FDA 510 (k) -approved device platform suitable for reducing blood culture contamination for sepsis testing.

“The goal of MHA Solutions is to provide our members and customers with the best possible products and services,” said Eddie Foster, President and CEO of MHA Solutions. “With its clinically proven results, Steripath meets our goal. We are excited to partner with Magnolia Medical to achieve a higher standard of care for the accuracy of sepsis diagnosis by offering our members new technology solutions and practice changes that can prevent patient harm from false positive blood cultures. We look forward to sharing the results of the HPIC sponsored Steripath pilot project with our members in over 100 hospitals. “

MHA Solutions and Magnolia Medical will also sponsor round table discussions with executives from MHA member hospitals on the national movement towards a blood culture contamination rate of 1 percent versus the current national average of 3 percent.

Blood cultures are the gold standard for detecting bloodstream infections, including sepsis. An estimated 58 million are carried out each year. A reduction in blood culture contamination from 3 percent to 1 percent corresponds to approximately 1.2 million fewer patients affected by a possible misdiagnosis of sepsis.

Source link


Comments are closed.